Prognostication and initiation of therapy in Polycythemia vera: Do we have it right?

Prognostication and initiation of therapy in Polycythemia vera: Do we have it right?

Indication for cytoreductive therapy in ET and PV: Do we have it right?Подробнее

Indication for cytoreductive therapy in ET and PV: Do we have it right?

Recent advances in the diagnosis, prognosis and survival predictions of patients with PVПодробнее

Recent advances in the diagnosis, prognosis and survival predictions of patients with PV

Molecular Prognostication in Essential Thrombocythemia and Polycythemia vera: Does it Matter?Подробнее

Molecular Prognostication in Essential Thrombocythemia and Polycythemia vera: Does it Matter?

Goals of Therapy in Polycythemia VeraПодробнее

Goals of Therapy in Polycythemia Vera

Case 2: The Diagnosis of Polycythemia VeraПодробнее

Case 2: The Diagnosis of Polycythemia Vera

“Masked” Polycythemia vera and Polycythemia vera “in Evolution”Подробнее

“Masked” Polycythemia vera and Polycythemia vera “in Evolution”

Treatment goals in Essential Thrombocythemia and Polycythemia veraПодробнее

Treatment goals in Essential Thrombocythemia and Polycythemia vera

Phase 2 REVIVE Clinical Trial for Polycythemia VeraПодробнее

Phase 2 REVIVE Clinical Trial for Polycythemia Vera

Polycythemia Vera: Prognostic MarkersПодробнее

Polycythemia Vera: Prognostic Markers

Initiating Treatment for Polycythemia VeraПодробнее

Initiating Treatment for Polycythemia Vera

Polycythemia vera (PV): Is resistance to hydroxyurea prognostic for adverse outcomes?Подробнее

Polycythemia vera (PV): Is resistance to hydroxyurea prognostic for adverse outcomes?

Clinical Control of Polycythemia VeraПодробнее

Clinical Control of Polycythemia Vera

Current therapy options and clinical outcomes analysis in patients with PVПодробнее

Current therapy options and clinical outcomes analysis in patients with PV

Meeting the Many Challenges of Uncontrolled Polycythemia VeraПодробнее

Meeting the Many Challenges of Uncontrolled Polycythemia Vera

Evolution of the Assessment of Clinical Benefit in Polycythemia VeraПодробнее

Evolution of the Assessment of Clinical Benefit in Polycythemia Vera

Polycythemia vera (PV): What prognostic factors are currently used to guide therapy selection?Подробнее

Polycythemia vera (PV): What prognostic factors are currently used to guide therapy selection?

Debate: Position of JAK2 inhibitors as second line therapy in Polycythemia veraПодробнее

Debate: Position of JAK2 inhibitors as second line therapy in Polycythemia vera

Practical Considerations of Polycythemia Vera TreatmentПодробнее

Practical Considerations of Polycythemia Vera Treatment

Understanding High-Risk vs Low-Risk Disease in PV, ET & MFПодробнее

Understanding High-Risk vs Low-Risk Disease in PV, ET & MF

Популярное